Dr. Reddy’s Laboratories Limited (RDY): Among the Best Indian Stocks for the Next 10 Years — Oct 9th, 2024

We recently compiled a list of the 10 Best Indian Stocks for Next 10 Years.In this article, we are going to take a look at where Dr. Reddy's Laboratories Limited (RDY) stands against the other Indian stocks. India's strong growth trajectory remains a compelling narrative on the back of re...

Dr. Reddy’s Subsidiary Triumphs in CAR-T Cell Therapy Trial — Oct 9th, 2024

Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s subsidiary Aurigene Oncology Limited reports positive Phase 1 results for India’s first novel CAR-T cell therapy trial in multiple myeloma patients. The therapy, Ribrecabtagene autoleucel, showed a 100% clinical respo...

Dr. Reddy’s Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month — Oct 14th, 2024

PRINCETON, N.J., October 14, 2024--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Inc., the U.S. arm of Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company headquartered in Hyderabad, India, today announced the launch of a comprehensive employee support program focused on menopau...

Dr. Reddy’s Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month — Oct 14th, 2024

PRINCETON, N.J., October 14, 2024--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Inc., the U.S. arm of Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company headquartered in Hyderabad, India, today announced the launch of a comprehensive employee support program focused on menopau...

Dr. Reddy’s Laboratories Limited (RDY): Among the Best Indian Stocks for the Next 10 Years — Oct 9th, 2024

We recently compiled a list of the 10 Best Indian Stocks for Next 10 Years.In this article, we are going to take a look at where Dr. Reddy's Laboratories Limited (RDY) stands against the other Indian stocks. India's strong growth trajectory remains a compelling narrative on the back of re...

Dr. Reddy’s Laboratories Limited (RDY): Among the Best Indian Stocks for the Next 10 Years — Oct 9th, 2024

We recently compiled a list of the 10 Best Indian Stocks for Next 10 Years.In this article, we are going to take a look at where Dr. Reddy's Laboratories Limited (RDY) stands against the other Indian stocks. India's strong growth trajectory remains a compelling narrative on the back of re...

Dr. Reddy’s Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month — Oct 14th, 2024

PRINCETON, N.J., October 14, 2024--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Inc., the U.S. arm of Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company headquartered in Hyderabad, India, today announced the launch of a comprehensive employee support program focused on menopau...

Dr. Reddy’s Expands Portfolio with $620M Investment — Sep 28th, 2024

Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s Laboratories has invested $620 million into its wholly-owned subsidiary, DRL SA, Switzerland, for the acquisition of Nicotinell and related brands. This strategic move, which is a related party transaction done at arm�...

Dr. Reddy’s signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries — Oct 2nd, 2024

HYDERABAD, India, October 02, 2024--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as "Dr. Reddy’s"), today announced that it has entered into a royalty-free non-exclusive voluntar...

Dr. Reddy’s Subsidiary Triumphs in CAR-T Cell Therapy Trial — Oct 9th, 2024

Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s subsidiary Aurigene Oncology Limited reports positive Phase 1 results for India’s first novel CAR-T cell therapy trial in multiple myeloma patients. The therapy, Ribrecabtagene autoleucel, showed a 100% clinical respo...

Dr. Reddy’s Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month — Oct 14th, 2024

PRINCETON, N.J., October 14, 2024--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Inc., the U.S. arm of Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company headquartered in Hyderabad, India, today announced the launch of a comprehensive employee support program focused on menopau...

Dr. Reddy’s Subsidiary Triumphs in CAR-T Cell Therapy Trial — Oct 9th, 2024

Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s subsidiary Aurigene Oncology Limited reports positive Phase 1 results for India’s first novel CAR-T cell therapy trial in multiple myeloma patients. The therapy, Ribrecabtagene autoleucel, showed a 100% clinical respo...

Dr. Reddy’s Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month — Oct 14th, 2024

PRINCETON, N.J., October 14, 2024--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Inc., the U.S. arm of Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company headquartered in Hyderabad, India, today announced the launch of a comprehensive employee support program focused on menopau...

Dr. Reddy’s Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month — Oct 14th, 2024

PRINCETON, N.J., October 14, 2024--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Inc., the U.S. arm of Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company headquartered in Hyderabad, India, today announced the launch of a comprehensive employee support program focused on menopau...

Dr. Reddy’s signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries — Oct 2nd, 2024

HYDERABAD, India, October 02, 2024--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as "Dr. Reddy’s"), today announced that it has entered into a royalty-free non-exclusive voluntar...

Dr. Reddy’s signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries — Oct 2nd, 2024

HYDERABAD, India, October 02, 2024--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as "Dr. Reddy’s"), today announced that it has entered into a royalty-free non-exclusive voluntar...

Dr. Reddy’s Subsidiary Triumphs in CAR-T Cell Therapy Trial — Oct 9th, 2024

Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s subsidiary Aurigene Oncology Limited reports positive Phase 1 results for India’s first novel CAR-T cell therapy trial in multiple myeloma patients. The therapy, Ribrecabtagene autoleucel, showed a 100% clinical respo...

Dr. Reddy’s signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries — Oct 2nd, 2024

HYDERABAD, India, October 02, 2024--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as "Dr. Reddy’s"), today announced that it has entered into a royalty-free non-exclusive voluntar...

Dr. Reddy’s Expands Portfolio with $620M Investment — Sep 28th, 2024

Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s Laboratories has invested $620 million into its wholly-owned subsidiary, DRL SA, Switzerland, for the acquisition of Nicotinell and related brands. This strategic move, which is a related party transaction done at arm�...

Dr. Reddy’s Laboratories Limited (RDY): Among the Best Indian Stocks for the Next 10 Years — Oct 9th, 2024

We recently compiled a list of the 10 Best Indian Stocks for Next 10 Years.In this article, we are going to take a look at where Dr. Reddy's Laboratories Limited (RDY) stands against the other Indian stocks. India's strong growth trajectory remains a compelling narrative on the back of re...

Dr. Reddy’s Laboratories Limited (RDY): Among the Best Indian Stocks for the Next 10 Years — Oct 9th, 2024

We recently compiled a list of the 10 Best Indian Stocks for Next 10 Years.In this article, we are going to take a look at where Dr. Reddy's Laboratories Limited (RDY) stands against the other Indian stocks. India's strong growth trajectory remains a compelling narrative on the back of re...

Dr. Reddy’s signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries — Oct 2nd, 2024

HYDERABAD, India, October 02, 2024--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as "Dr. Reddy’s"), today announced that it has entered into a royalty-free non-exclusive voluntar...

Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India’s First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma — Oct 8th, 2024

BENGALURU, India & HYDERABAD, India, October 08, 2024--(BUSINESS WIRE)--Aurigene Oncology Limited, a wholly-owned subsidiary of Dr. Reddy’s Laboratories Limited and a clinical stage biotech committed to bringing in novel and effective therapeutics for the treatment of cancer, has announc...

Dr. Reddy’s Subsidiary Triumphs in CAR-T Cell Therapy Trial — Oct 9th, 2024

Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s subsidiary Aurigene Oncology Limited reports positive Phase 1 results for India’s first novel CAR-T cell therapy trial in multiple myeloma patients. The therapy, Ribrecabtagene autoleucel, showed a 100% clinical respo...

Dr. Reddy’s Expands Portfolio with $620M Investment — Sep 28th, 2024

Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s Laboratories has invested $620 million into its wholly-owned subsidiary, DRL SA, Switzerland, for the acquisition of Nicotinell and related brands. This strategic move, which is a related party transaction done at arm�...

Dr. Reddy’s Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month — Oct 14th, 2024

PRINCETON, N.J., October 14, 2024--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Inc., the U.S. arm of Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company headquartered in Hyderabad, India, today announced the launch of a comprehensive employee support program focused on menopau...

Dr. Reddy’s Laboratories Limited (RDY): Among the Best Indian Stocks for the Next 10 Years — Oct 9th, 2024

We recently compiled a list of the 10 Best Indian Stocks for Next 10 Years.In this article, we are going to take a look at where Dr. Reddy's Laboratories Limited (RDY) stands against the other Indian stocks. India's strong growth trajectory remains a compelling narrative on the back of re...

Dr. Reddy’s Laboratories Limited (RDY): Among the Best Indian Stocks for the Next 10 Years — Oct 9th, 2024

We recently compiled a list of the 10 Best Indian Stocks for Next 10 Years.In this article, we are going to take a look at where Dr. Reddy's Laboratories Limited (RDY) stands against the other Indian stocks. India's strong growth trajectory remains a compelling narrative on the back of re...

Dr. Reddy’s Laboratories Limited (RDY): Among the Best Indian Stocks for the Next 10 Years — Oct 9th, 2024

We recently compiled a list of the 10 Best Indian Stocks for Next 10 Years.In this article, we are going to take a look at where Dr. Reddy's Laboratories Limited (RDY) stands against the other Indian stocks. India's strong growth trajectory remains a compelling narrative on the back of re...

Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India’s First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma — Oct 8th, 2024

BENGALURU, India & HYDERABAD, India, October 08, 2024--(BUSINESS WIRE)--Aurigene Oncology Limited, a wholly-owned subsidiary of Dr. Reddy’s Laboratories Limited and a clinical stage biotech committed to bringing in novel and effective therapeutics for the treatment of cancer, has announc...

Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India’s First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma — Oct 8th, 2024

BENGALURU, India & HYDERABAD, India, October 08, 2024--(BUSINESS WIRE)--Aurigene Oncology Limited, a wholly-owned subsidiary of Dr. Reddy’s Laboratories Limited and a clinical stage biotech committed to bringing in novel and effective therapeutics for the treatment of cancer, has announc...

Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India’s First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma — Oct 8th, 2024

BENGALURU, India & HYDERABAD, India, October 08, 2024--(BUSINESS WIRE)--Aurigene Oncology Limited, a wholly-owned subsidiary of Dr. Reddy’s Laboratories Limited and a clinical stage biotech committed to bringing in novel and effective therapeutics for the treatment of cancer, has announc...

Dr. Reddy’s signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries — Oct 2nd, 2024

HYDERABAD, India, October 02, 2024--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as "Dr. Reddy’s"), today announced that it has entered into a royalty-free non-exclusive voluntar...

Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India’s First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma — Oct 8th, 2024

BENGALURU, India & HYDERABAD, India, October 08, 2024--(BUSINESS WIRE)--Aurigene Oncology Limited, a wholly-owned subsidiary of Dr. Reddy’s Laboratories Limited and a clinical stage biotech committed to bringing in novel and effective therapeutics for the treatment of cancer, has announc...

Dr. Reddy’s Expands Portfolio with $620M Investment — Sep 28th, 2024

Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s Laboratories has invested $620 million into its wholly-owned subsidiary, DRL SA, Switzerland, for the acquisition of Nicotinell and related brands. This strategic move, which is a related party transaction done at arm�...

Dr. Reddy’s signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries — Oct 2nd, 2024

HYDERABAD, India, October 02, 2024--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as "Dr. Reddy’s"), today announced that it has entered into a royalty-free non-exclusive voluntar...

Dr. Reddy’s signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries — Oct 2nd, 2024

HYDERABAD, India, October 02, 2024--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as "Dr. Reddy’s"), today announced that it has entered into a royalty-free non-exclusive voluntar...

Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India’s First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma — Oct 8th, 2024

BENGALURU, India & HYDERABAD, India, October 08, 2024--(BUSINESS WIRE)--Aurigene Oncology Limited, a wholly-owned subsidiary of Dr. Reddy’s Laboratories Limited and a clinical stage biotech committed to bringing in novel and effective therapeutics for the treatment of cancer, has announc...

Dr. Reddy’s Expands Portfolio with $620M Investment — Sep 28th, 2024

Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s Laboratories has invested $620 million into its wholly-owned subsidiary, DRL SA, Switzerland, for the acquisition of Nicotinell and related brands. This strategic move, which is a related party transaction done at arm�...

Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India’s First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma — Oct 8th, 2024

BENGALURU, India & HYDERABAD, India, October 08, 2024--(BUSINESS WIRE)--Aurigene Oncology Limited, a wholly-owned subsidiary of Dr. Reddy’s Laboratories Limited and a clinical stage biotech committed to bringing in novel and effective therapeutics for the treatment of cancer, has announc...

Dr. Reddy’s signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries — Oct 2nd, 2024

HYDERABAD, India, October 02, 2024--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as "Dr. Reddy’s"), today announced that it has entered into a royalty-free non-exclusive voluntar...

Dr. Reddy’s Subsidiary Triumphs in CAR-T Cell Therapy Trial — Oct 9th, 2024

Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s subsidiary Aurigene Oncology Limited reports positive Phase 1 results for India’s first novel CAR-T cell therapy trial in multiple myeloma patients. The therapy, Ribrecabtagene autoleucel, showed a 100% clinical respo...

Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India’s First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma — Oct 8th, 2024

BENGALURU, India & HYDERABAD, India, October 08, 2024--(BUSINESS WIRE)--Aurigene Oncology Limited, a wholly-owned subsidiary of Dr. Reddy’s Laboratories Limited and a clinical stage biotech committed to bringing in novel and effective therapeutics for the treatment of cancer, has announc...

Dr. Reddy’s Subsidiary Triumphs in CAR-T Cell Therapy Trial — Oct 9th, 2024

Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s subsidiary Aurigene Oncology Limited reports positive Phase 1 results for India’s first novel CAR-T cell therapy trial in multiple myeloma patients. The therapy, Ribrecabtagene autoleucel, showed a 100% clinical respo...

Dr. Reddy’s Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month — Oct 14th, 2024

PRINCETON, N.J., October 14, 2024--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Inc., the U.S. arm of Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company headquartered in Hyderabad, India, today announced the launch of a comprehensive employee support program focused on menopau...

Dr. Reddy’s Subsidiary Triumphs in CAR-T Cell Therapy Trial — Oct 9th, 2024

Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s subsidiary Aurigene Oncology Limited reports positive Phase 1 results for India’s first novel CAR-T cell therapy trial in multiple myeloma patients. The therapy, Ribrecabtagene autoleucel, showed a 100% clinical respo...